The Orphan Drug designation is based on data from the dose escalation phase of the open-label phase 1/2 study.

Peptides, short chains of amino acids, have been extensively studied for their potential role in mitigating bone degradation.

An analysis of genetic sequencing data and gene and protein expression studies from patients with yellow nail syndrome (YNS) ...